Select a community
All Communities
Home > Community Treatment Reports > Cyclobenzaprine Treatment Report
What is Cyclobenzaprine?

Cyclobenzaprine is a centrally-acting skeletal muscle relaxant used in the treatment of muscle spasm associated with acute painful musculoskeletal conditions.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Muscle spasms 180 42
Fibromyalgia 151 40
Stiffness/Spasticity 101 18
Pain 74 21
Other 67 18
Back pain 45 10

See all 689 patients currently taking Cyclobenzaprine


Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
5 3%
Moderate
25 17%
Mild
52 36%
None
63 43%

Most commonly reported side effects

Drowsiness
51 35%
dry mouth
29 20%
Hangover effect
26 18%
Poor Concentration
21 14%
Constipation
15 10%
Sleepiness
12 8%
  • Mild
  • Moderate
  • Severe

Dosages

Top 10 dosages based on patients currently taking Cyclobenzaprine. See all 45 dosages ►

  0 10mg as needed 0.5 10mg as needed 10 mg all the time (24/7) 10 mg as needed 10mg as needed 10mg daily 15mg as needed 1mg as needed 20 10mg as needed 20 mg all the time (24/7) 20 mg as needed 20mg as needed 2 10mg as needed 2 5mg as needed 2 7.5mg as needed 30 mg as needed 30mg as needed 3 10mg as needed 3 5mg as needed 40mg as needed 500mg as needed 50 mg all the time (24/7) 5 mg as needed 5mg as needed 7.5mg as needed daily mg as needed 10 mg yearly 30 mg monthly 10 mg weekly 5 mg daily 40 mg weekly 7.5 mg daily 7.5 mg one time 10 mcg daily 10 mg daily 15 mg daily 20 mg daily 25 mg daily 30 mg daily 40 mg daily 50 mg daily 60 mg daily 80 mg daily 100 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 6 Number of Patients: 6 10 Number of Patients: 10 135 Number of Patients: 135 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 5 Number of Patients: 5 4 Number of Patients: 4 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 3 Number of Patients: 3 7 Number of Patients: 7 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 51 Number of Patients: 51 5 Number of Patients: 5 6 Number of Patients: 6 5 Number of Patients: 5 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 56 Number of Patients: 56 1 Number of Patients: 1 5 Number of Patients: 5 1 Number of Patients: 1 1 Number of Patients: 1 203 Number of Patients: 203 28 Number of Patients: 28 64 Number of Patients: 64 2 Number of Patients: 2 67 Number of Patients: 67 4 Number of Patients: 4 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Cyclobenzaprine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
59 40% Did not seem to work: 40%
Other
35 23% Other: 23%
Doctor's advice
27 18% Doctor's advice: 18%
Course of treatment ended
23 15% Course of treatment ended: 15%
Side effects too severe
15 10% Side effects too severe: 10%
Expense
6 4% Expense: 4%
Personal research
3 2% Personal research: 2%

See all 141 patients who’ve stopped taking Cyclobenzaprine

Duration See details about how long patients take this treatment ▼

Currently Taking Cyclobenzaprine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
14
24
52
117
85
153

Stopped Taking Cyclobenzaprine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
19
32
21
20
11
36

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
81 56%
Usually
48 33%
Sometimes
11 8%
Never
5 3%

Burden

Difficulty being on treatment

Very
4 3%
Somewhat
14 10%
A little
24 17%
Not at all
103 71%

Cost

Paid out of pocket

$200+
0 0%
$100-199
1 1%
$50-99
0 0%
$25-49
11 8%
< $25
91 63%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 20, 2009.